GLP-3R
| Vendor | Price | 10mg cost | Updated | Actions |
|---|---|---|---|---|
| Lost Coast Aminos 9.5/10 COA ✓Ships: USCredit/debit card · Zelle Verification & shipping9.5/10 COA ✓Ships: USCredit/debit card · Zelle | $27.00 | $27.00Checked 6 days ago | 6 days ago | Buy GLP-3R from Lost Coast Aminos |
| Noble Sciences 10/10 COA ✓Ships: USCredit/debit card (Intuit/QuickBooks) · Zelle Verification & shipping10/10 COA ✓Ships: USCredit/debit card (Intuit/QuickBooks) · Zelle | $35.10 | $35.10Checked aug 1, 2026 | Aug 1, 2026 | Buy GLP-3R from Noble Sciences |
| Step One Ventures 8/10 COA ✓Ships: USCredit/debit card · Zelle Verification & shipping8/10 COA ✓Ships: USCredit/debit card · Zelle | $36.00 | $36.00Checked jul 22, 2026 | Jul 22, 2026 | Buy GLP-3R from Step One Ventures |
| NextGen Peptides 8/10 COA ✓Ships: USVisa · American Express Verification & shipping8/10 COA ✓Ships: USVisa · American Express | $37.80 | $37.80Checked jul 24, 2026 | Jul 24, 2026 | Buy GLP-3R from NextGen Peptides |
| Puratek Peptides 7/10 COA ✓Ships: USZelle · Cash App Verification & shipping7/10 COA ✓Ships: USZelle · Cash App | $40.46 | $40.46Checked jul 31, 2026 | Jul 31, 2026 | Buy GLP-3R from Puratek Peptides |
| Ascending Labs 8.5/10 COA ✓Ships: USCredit/debit card Verification & shipping8.5/10 COA ✓Ships: USCredit/debit card | $40.50 | $40.50Checked jul 25, 2026 | Jul 25, 2026 | Buy GLP-3R from Ascending Labs |
Current market data
GLP-3R Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current whole-package cost to obtain at least 10mg of GLP-3R is $27.00 from Lost Coast Aminos. The median 10mg cost across vendors is $71.09.
- Lowest 10mg cost
- $27.00 Lost Coast Aminos
- Median 10mg cost
- $71.09 One normalized offer per vendor
- Lowest package total
- $27.00 Lost Coast Aminos · package size may differ
- Public COA coverage
- 95% 82 of 86 vendors
What the market shows
PeptidePrices found 307 in-stock listings from 86 vendors. The lowest 10mg cost is 62% below the normalized vendor median.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research details
GLP-3R — research data
Overview
About GLP-3R
Mechanism of action
Triple agonist of GLP-1, GIP, and glucagon receptors. Combines appetite suppression, improved insulin sensitivity, and increased energy expenditure.
Safety profile
Nausea, vomiting, diarrhea, reduced appetite, potential cardiovascular effects; still in clinical trials — full profile not established. · Phase II showed strong efficacy/tolerability; GI side effects; novel mechanism; promising safety data
Storage
Stability & handling
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Personal or family history of MTC (by class effect — applies across GLP-1/GIP/Glucagon agonists).
MEN 2 syndrome.
Other GLP-1 agonists (Semaglutide, Tirzepatide) — do not combine.
Research products are not for human use. Looking for clinician-supervised care instead? GLP-3R is investigational; compare currently available clinician-guided GLP-1 options.
Compare supervised options →Related pages
More on GLP-3R
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- Phase 2 NEJM trial demonstrated up to 24.2% mean body weight reduction at 48 weeks — the highest reported for any investigational anti-obesity agent at the time.
- TRIUMPH-4 Phase 3 topline (Eli Lilly, Dec 2025) reported ~28.7% average body weight reduction at 68 weeks in adults with obesity and knee osteoarthritis; TRANSCEND-T2D-1 topline (Mar 2026) showed ~−2.0% HbA1c and ~16.8% weight reduction in type 2 diabetes.